

---

(12) UK Patent Application (19) GB (11) 2 125 398 A

---

- (21) Application No 8317365  
(22) Date of filing 27 Jun 1983  
(30) Priority data  
(31) 3979/82  
(32) 29 Jun 1982  
(31) 4267/82  
(32) 13 Jul 1982  
(31) 6950/82  
(32) 30 Nov 1982  
(31) 6951/82  
(32) 30 Nov 1982  
(31) 7494/82  
(32) 22 Dec 1982  
(31) 7495/82  
(32) 22 Dec 1982  
(31) 1256/83  
(32) 9 Mar 1983  
(33) Switzerland (CH)  
(43) Application published  
7 Mar 1984  
(51) INT CL<sup>3</sup>  
C07D 451/12 A61K 31/55  
31/445 C07D 451/14  
453/02 471/08 // (C07D  
471/08 221/00 223/00)  
(52) Domestic classification  
C2C 1204 1340 1343  
1356 1410 1473 1512  
1547 1548 155X 213 214  
215 220 226 227 22X  
22Y 246 247 250 251 252  
253 254 25Y 270 280 281  
28X 29X 29Y 302 30Y  
311 313 314 315 31Y 321  
322 323 32Y 332 337 338  
340 342 346 34Y 351 355  
35X 360 362 364 366  
367 368 36Y 37X 43X  
440 449 455 45Y 491 500  
509 50Y 579 603 604 620  
621 623 624 625 627 628  
62X 660 661 662 665  
668 669 670 672 675 678  
679 67X 698 699 709  
719 71Y 721 802 80Y AA  
BC KA KF KH LM LS MM  
MV NF WC  
U1S 2415 2417 2418 C2C  
(56) Documents cited  
None  
(58) Field of search  
C2C  
(71) Applicant  
Sandoz Ltd.,  
(Switzerland),  
35 Lichtstrasse,  
CH-4002 Basle,  
Switzerland  
(72) Inventors  
Peter Donatsch,  
Gunter Engel,  
Bruno Hugli,  
Brian Peter Richardson,  
Paul Stadler  
(74) Agent and/or address for  
service  
B. A. Yorke & Co.,  
98 The Centre,  
Feltham,  
Middlesex,  
TW13 4EP  
(54) Bridged piperidyl esters and  
amides  
(57) The dicarbocyclic, heterocyclic and  
substituted benzolic acid alkylene  
bridged piperidyl amides and esters  
are serotonin M antagonists.

GB 2 125 398 A

## SPECIFICATION

## Benzoic acid piperidyl ester derivatives


This invention relates to benzoic acid piperidyl ester derivatives, including analogues of benzoic acid e.g. polycarboxylic and heterocyclic carboxylic acids.

5 The present invention provides a di-carboxylic or heterocyclic carboxylic acid alkylene bridged piperidyl ester or amide or a substituted benzoic acid alkylene bridged piperidyl ester or amide, with the provisos that


- a) any benzoic acid ester having the alkylene bridge between two ring piperidyl carbon atoms is substituted in the phenyl ring in at least one of the ortho or meta positions,
  - 10 b) any benzoic acid ester unsubstituted in both the ortho positions, or having halogen or alkyl in at least one of the ortho positions and only hydrogen or halogen in the meta and para positions, and having the alkylene bridge between the ring piperidyl carbon atoms, has a minimum of 3 carbon atoms in the alkylene bridge,
  - 15 c) any benzoic acid ester having an alkylene bridge between the piperidyl nitrogen atom and a ring carbon atom and having an oxy substituent has either at least one substituent other than an oxy substituent or has only 2 oxy substituents in the benzoic acid nucleus,
  - d) any monocyclic heterocycle carboxylic acid amide or ester the heterocycle of which is a six membered ring containing ring nitrogen atoms or a cyclic heterocyclic carboxylic acid amide the heterocycle of which contains two oxygen atoms, has an alkylene bridge between the
  - 20 piperidyl nitrogen atom and a ring carbon atom,
  - e) any benzoic acid amide has the alkylene bridge bound between the ring piperidyl nitrogen atom and a ring carbon atom,
  - f) any benzoic acid amide does not have alkyl or hydroxy or halogen substituents in any of the ortho positions, and
  - 25 g) thienoyl and naphthoyl 8-aza-bicyclo[3.2.1]oct-3-yl esters are excluded.
- and salts thereof, e.g. acid addition salts and quaternary ammonium salts e.g. on the piperidyl nitrogen atom. All these compounds and salts are hereinafter referred to as compounds of the invention.

30 The compounds may be substituted where desired. Any substituents on the benzoic acid esters and amides do not form a ring. In one group of compounds the acid nucleus is di-carboxylic. In another group of compounds the acid nucleus is heterocyclic, preferably bicyclic and conveniently containing one ring heteroatom. Conveniently the alkylene bridge has a minimum of 3 carbon atoms. Alternatively the bridge is attached to the piperidyl nitrogen atom.

Also the present invention provides a compound of formula I




wherein A is a group of formula II




wherein

- the free valence is attached to either fused ring,
- 40 X is  $-CH_2-$ ,  $-NR_3-$ ,  $-O-$ , or  $-S-$ ,
- R<sub>1</sub> and R<sub>2</sub> independently are hydrogen, halogen, (C<sub>1-4</sub>)alkoxy, hydroxy, amino, (C<sub>1-4</sub>)alkylamino, di(C<sub>1-4</sub>)alkylamino, mercapto, or (C<sub>1-4</sub>)alkylthio, and
- R<sub>3</sub> is hydrogen, (C<sub>1-4</sub>)alkyl, (C<sub>3-8</sub>)alkenyl, aryl, or aralkyl,
- or a group of formula III



wherein

- R<sub>4</sub> to R<sub>7</sub> independently are hydrogen, amino, nitro, (C<sub>1-4</sub>)alkylamino, di(C<sub>1-4</sub>)alkylamino, halogen, (C<sub>1-4</sub>)alkoxy, (C<sub>1-4</sub>)alkyl, (C<sub>1-4</sub>)alkanoylamino or pyrrolyl, with the proviso that at least one of R<sub>4</sub> and R<sub>5</sub> is other than hydrogen,
- 50 B is  $-O-$  or  $-NH-$ ,
- D is a group of formula IV



IV


wherein

n is 2, 3 or 4,

R<sub>8</sub> is hydrogen, (C<sub>1-7</sub>)alkyl, (C<sub>3-5</sub>)alkenyl, or aralkyl,

5 or a group of formula V

5



V

with the further provisos (i) that when A is a group of formula III, and B is —NH—, then D is a group of formula V, (ii) that when A is a group of formula III wherein either R<sub>4</sub> is hydrogen, or wherein R<sub>4</sub> is halogen or alkyl and R<sub>5</sub> to R<sub>7</sub> are chosen from halogen or hydrogen, and B is —O— and D is a group of formula IV, then n is 3 or 4, that iii) when A is a group of formula III and one of R<sub>4</sub> to R<sub>7</sub> is alkoxy, and D is a group of formula V then either one of the others of R<sub>4</sub> to R<sub>7</sub> is other than hydrogen and alkoxy or only two of R<sub>4</sub> to R<sub>7</sub> are alkoxy, v) that when A is a group of formula III wherein R<sub>4</sub> is alkyl or halogen, then B is —O—, as well as acid addition salts and quaternary ammonium salts thereof.

Any alkyl moiety is methyl, ethyl or propyl. Alkoxy is preferably methoxy or ethoxy. Aralkyl is conveniently aryl(C<sub>1-4</sub>)alkyl. Alkenyl is preferably allyl or methallyl. Any aryl moiety is preferably unsubstituted phenyl or phenyl mono- or poly-substituted by (C<sub>1-4</sub>)alkyl, e.g. methyl, halogen, e.g. fluorine, hydroxy, or (C<sub>1-4</sub>)alkoxy, e.g. methoxy. Preferably any substituted aryl group is mono-substituted. Aralkyl is conveniently benzyl. Halogen is fluorine, chlorine, bromine or iodine.

A is conveniently a group of formula II.  
In the group of formula II, the carbonyl side chain may be attached to the ring carbon atom in positions 2, 3, 4, 5, 6 or 7 of the nucleus, but preferably in position 4 and 5. Most preferably the carbonyl group is attached to the ring containing X especially in position 3. Preferably A is indole.

R<sub>1</sub> is attached to the ring carbon atom in position 4, 5, 6 or 7 of the nucleus, preferably position 5 and R<sub>2</sub> is attached to the ring carbon atom in position 2 or 3 of the nucleus. Tautomers are also covered by formula I e.g. when R<sub>2</sub> is hydroxy or mercapto in the 2 position.

R<sub>3</sub> is conveniently hydrogen or alkyl. Conveniently n is 3 or 4, more preferably 3.

In a group of formula III conveniently  
R<sub>4</sub> is halogen, (C<sub>1-4</sub>)alkylamino or (C<sub>1-4</sub>)alkoxy;  
R<sub>5</sub> is hydrogen or halogen;  
R<sub>6</sub> is hydrogen, amino, nitro, (C<sub>1-4</sub>)alkylamino, or di(C<sub>1-4</sub>)alkylamino, halogen or 1-pyrrolyl;  
R<sub>7</sub> is hydrogen or halogen;

conveniently R<sub>8</sub> is other than hydrogen, halogen or pyrrolyl.

In the group of formula III R<sub>7</sub> is preferably halogen and is preferably chlorine or iodine and especially chlorine.


Other examples of the group of formula III include 3,5-dimethoxyphenyl, 3,5-dimethylphenyl and especially 3,5-dichlorophenyl. Alternatively the group of formula III may be 3-chloro-, 3-methyl- or 3,4,5-trimethoxyphenyl.

The group IV may exist in different conformations. For example the six-membered ring containing the nitrogen atom and the carbon atom to which the B-moiety is attached—hereinafter referred to as the piperidyl ring—may exist in the chair or boat conformations or in an intermediate conformation.

The moiety B may have two different configurations. These can be appreciated by making group IV have a conformation wherein a reference plane may be drawn through the carbon atoms of the piperidyl ring and the nitrogen atom is above the plane and the alkylene bridge is below the plane. The B moiety has the α-configuration when it is below the plane on the same side as the alkylene bridge. This corresponds to the endo configuration and also to the configuration in tropine etc. The B moiety has the β-configuration when it is above the plane on the same side as the nitrogen bridge. This corresponds to the exo configuration and also the configuration in pseudotropine etc. Used hereinafter is the exo/endo nomenclature. The endo isomers are preferred.

R<sub>8</sub> is preferably alkyl and especially methyl.  
A group of formula V is also known as quinuclidinyl. Conveniently this is 3- or 4-quinuclidinyl and especially 3-quinuclidinyl.

A group of compounds comprises compounds of formula Ipa.



lpa


wherein

- $R_{4pa}$  is halogen,  $(C_{1-4})$ alkylamino, or  $(C_{1-4})$ alkoxy,  
 $R_{5pa}$  is hydrogen,  
 $R_{6pa}$  is amino,  $(C_{1-4})$ alkylamino, or di $(C_{1-4})$ alkylamino,  
 $R_{7pa}$  is hydrogen or fluorine, chlorine or bromine, and  
 $R_{8pa}$  is hydrogen,  $(C_{1-7})$ alkyl or aralkyl,  
 as well as acid addition salts and quaternary ammonium salts thereof.

5

- Another group of compounds comprises benzoic acid isopelletierine (homotropane) esters, in  
 10 particular compounds of formula lpb

10




lpb

wherein

- $R_{4pa}$ ,  $R_{5pa}$ ,  $R_{6pa}$ ,  $R_{8pa}$  are as defined above and  
 $R_{7pb}$  is hydrogen or halogen,  
 15 as well as acid addition salts and quaternary ammonium salts thereof.

15

A group of compounds comprises compounds of formula lqa




lqa

wherein

- the free valence is attached to either fused ring, and  
 $n'$  is 2 or 3, and  
 $R_1$ ,  $R_2$ ,  $R_3$  and  $R_8$  are as defined above,  
 as well as acid addition salts and quaternary ammonium salts thereof.

20

Another group of compounds comprises indole carboxylic acid tropine and isopelletierine  
 (homotropane) esters, particularly of formula lqb



lqb

25

25


wherein

- the free valence is attached to either fused ring, and  
 $R_{1qb}$  and  $R_{2qb}$  are independently hydrogen, halogen or  $(C_{1-4})$ alkyl,  
 $R_{3qb}$  is hydrogen or  $(C_{1-4})$ alkyl,

$R_{8qb}$  is hydrogen or  $(C_{1-7})$ alkyl or aralkyl, and  $n'$  is as defined above,

as well as acid addition salts and quaternary ammonium salts thereof.

A further group of compounds comprises indole carboxylic acid tropine and isopelletierine (homotropane) amides, in particular of formula Iqc



wherein


the free valence is attached to either fused ring, and

$R_{2qc}$  is as  $R_2$  defined above other than  $(C_{1-4})$ alkoxy and hydroxy, and

$n'$ ,  $R_1$ ,  $R_3$ ,  $R_8$  are as defined above,

as well as acid addition salts and quaternary ammonium salts thereof.


Another group of compounds comprises benzoic acid quinuclidinyl esters, in particular compounds of formula Isa



wherein

$R_{4pa}$ ,  $R_{5pa}$ ,  $R_{6pa}$ , and  $R_{7pb}$  are as defined above as well as acid addition salts and quaternary ammonium salts thereof.

A further group of compounds comprises benzoic acid quinuclidinyl amides in particular compounds of formula Isb



wherein

$R_{4pa}$ ,  $R_{5pa}$ ,  $R_{6pa}$  and  $R_{7pb}$  are as defined above, as well as acid addition salts and quaternary ammonium salts thereof.

The present invention furthermore provides a process for the production of a compound of a invention which includes the step of condensing an appropriate di-carbocyclic or heterocyclic carboxylic acid or benzoic acid or a reactive acid derivative thereof, or a precursor of the acid or derivative, with an appropriate alkylene bridged piperidyl amine or piperidinol, or a precursor thereof, and as necessary converting the resultant piperidyl ester or amide, or acid addition salt or quaternary ammonium salt thereof into the required piperidyl ester or amide or acid addition salt or quaternary ammonium salt thereof and recovering the resultant piperidyl ester or amide as such or as an acid addition salt or as a quaternary ammonium salt thereof.

In particular the present invention provides a process for the production for a compound of formula I as well as acid addition salts thereof or quaternary ammonium salts thereof which includes the step of

a) condensing an appropriate compound of formula VI



VI

wherein

A is as defined above,  
a reactive derivative thereof,  
or a precursor of the acid or derivative,

5 with an appropriate compound of formula VII

5

HB—D

VII

wherein

B and D are as defined above,  
or a precursor of the compound, or

10 b) alkylating a compound of formula I having a secondary amino group to produce a compound of formula I with a tertiary amino group, 10

c) deprotecting any protected form of a compound of formula I to obtain a compound of formula I,

d) halogenating a compound of formula I wherein A is a group of formula II and R<sub>2</sub> is hydrogen to obtain the corresponding compound wherein R<sub>2</sub> is halogen, or

15 e) alkoxylating a compound of formula I wherein A is a group of formula II and R<sub>2</sub> is halogen to obtain the corresponding compound wherein R<sub>2</sub> is alkoxy, and 15

recovering the resultant compound of formula I as such or as an acid addition salt or as a quaternary ammonium salt thereof.

20 The condensation process of the invention to obtain amides and esters may be effected in conventional manner for analogous compounds. 20

For example the carboxylic acid group may be activated in the form of a reactive acid derivative, especially for the production of amides.

25 Suitable reactive acid derivatives may be formed by reaction with N,N'-carbonyl-diimidazole producing an intermediate carboxylic acid imidazolide, or with N-hydroxy-succinimide. Alternatively an acid chloride may be used, e.g. produced by reaction with oxalyl chloride. 25

For production of esters, the alcohol may be used e.g. in the form of an alkali metal salt, preferably the lithium salt. Such salts may be produced in conventional manner, e.g. by reaction of a n-butyl lithium with the alcohol in tetrahydrofuran. If desired a heterocyclic or tertiary amine, e.g. pyridine or triethylamine, may be present, especially for the production of amides.

30 Suitable reaction temperatures may be from about -10° to about 10°. In the case of compounds wherein B is NH and D is a group of formula V the reaction temperature may be for example up to about 100°C, e.g. in boiling methanol or ethanol. 30

Other suitable inert organic solvents include, e.g. tetrahydrofuran or dimethoxyethane.

35 In these reactions the endo or exo configuration of the substituent B in the group of formula IV is believed to be maintained. The compound of formula VII may be reacted if desired as a mixture of endo and exo isomers and the pure endo or exo isomer isolated, e.g. by chromatography or crystallization. 35

The compounds of the invention may be converted into other compounds of the invention, e.g. in conventional manner. Some interconversions are exemplified in processes b), c), d) and e).

40 The alkylation reaction of process b) may be effected in conventional manner. Any free amino group may be alkylated especially compounds of formula II wherein X=NH. Appropriate alkylation conditions include reaction with an alkyl halide in the presence of a sodium alcoholate. Suitable temperatures may be from about -50° to about -30°C. 40

The deprotection reaction of process c) is specifically suitable for the production of compounds with secondary amino groups, e.g. R<sub>8</sub>=H in the group of formula IV or primary amino groups, e.g.

45 R<sub>8</sub>=NH<sub>2</sub>. 45

For example a compound of formula I may be produced in protected form, e.g. R<sub>8</sub> being replaced by a secondary amino protecting group such as benzyl.

The benzyl group may be split off in conventional manner, e.g. by hydrogenation to produce the corresponding compound of formula I wherein R<sub>8</sub> is hydrogen.

50 Suitably the hydrogenation may be effected in the presence of a palladium on active charcoal at room temperature or at a slightly elevated temperature. Suitable solvents include acetic acid, ethyl acetate or ethanol. 50

A primary amino group as R<sub>8</sub> may be protected by e.g. N-benzyloxycarbonyl. This group may be split off by hydrogenation analogously to that indicated above. In the presence of a benzyl group the N-benzyloxycarbonyl group is generally split off first so that this group may be selectively split off.

55 Also the amino group may be in the form of a nitro group. This can be selectively reduced in conventional manner, e.g. by iron in hydrochloric acid. 55

Halogenation according to process d) may be effected in conventional manner. For example with N-chloro-succinimide may lead to chlorination. Such reactions may be effected in a suspension in chloroform. Reaction with N-iodo-succinimide may alternatively lead to iodination.

60 Replacement of reactive halogen groups according to process e) may be effected in conventional manner e.g. by reaction with a appropriate alcohol at e.g. room temperature from 10 to 20 hours at least. 60

A precursor of a starting material may be employed if desired. Such a precursor may be capable

	of being converted into the starting material in conventional manner but instead the process of the invention is carried out with the precursor and the other starting material or materials or a precursor thereof. The resultant product is converted into the compound of the invention in conventional manner, e.g. by using the same reaction conditions by which the precursor may be converted into the starting material. Typical precursors include protected forms of a starting material, e.g. wherein amino groups are temporarily protected.	5
	The compounds of the invention may be isolated and purified in conventional manner.	
10	Insofar as the production of any starting material is not particularly described herein, it is known, or may be produced in analogous manner to known compounds, in analogous manner to that described herein, e.g. the examples, or to known procedures for analogous compounds.	10
	Compounds of formula VII wherein B is —NH—, D is a group of formula IV wherein n is 4 are new and form part of the present invention. These compounds have never been specifically suggested before although they fall under various generic disclosures.	
15	The compounds are useful intermediates e.g. for the preparation of amides as described herein which have an interesting pharmacological profile and e.g. have never been disclosed as Serotonin M antagonists and having other activities disclosed hereinafter.	15
20	These compounds of formula VII may for example be produced by reduction of the corresponding oxime, like the other compounds of formula VII wherein B is —NH—. Compounds of formula VII wherein B is —O— may be produced in conventional manner by reduction of the corresponding ketone.	20
	All the above reductions may be effected, e.g. by catalytic hydrogenation, e.g. over platinum (believed to lead primarily to endo isomers), Bouveault-Blanc reaction procedures, e.g. sodium/amyl alcohol or butanol (believed to lead primarily to exo isomers), or aluminium hydride procedures, or sodium borohydride (often leading to mixture of endo/exo isomers).	
25	Any mixture of the exo and endo forms may be separated by chromatography.	25
	Free base forms of compounds of the invention may be converted into salt forms. For example acid addition salts may be produced in conventional manner by reacting with a suitable acid, and vice versa. Suitable acids for salt formation include hydrochloric acid, malonic acid, hydrobromic acid, maleic acid, malic acid, fumaric acid, methanesulphonic acid, oxalic acid, and tartaric acid. Quaternary ammonium salts of the compounds of the invention may be produced in conventional manner, e.g. by reaction with methyl iodide.	
30	In the following examples all temperatures are in degrees Centigrade and are uncorrected. All n.m.r. spectra values are in ppm (tetramethylsilane=0 ppm).	30
	<b>Nomenclature</b>	
35	Endo-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl=tropyl or $\alpha$ -tropyl Exo-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl=pseudo- or $\beta$ -tropyl Endo-9-methyl-9-aza-bicyclo[3.3.1]non-3-yl=isopelletierinyl or $\alpha$ -homo-tropanyl Exo-9-methyl-9-aza-bicyclo[3.3.1]non-3-yl= $\beta$ -isopelletierinyl or $\beta$ -homo-tropanyl or pseudopelletierinyl	35
40	1-aza-bicyclo[2.2.2]octyl=quinuclidinyl	40
	The configurations of the title compounds of Example A-2; A-3; and B-6 have been confirmed by x-ray analysis. The configuration of the remaining compounds is believed to follow that of the starting materials of formula VII which were used pure, except where otherwise stated.	
45	In the tables the columns heading "configuration" gives the indicated configuration of the group B—D, i.e. endo or exo. The column heading "Prep" gives the number of the Example in the A series describing the preparation process.	45
	<b>Abbreviations used:—</b>	
	III-I =5-chloro-2-methoxy-4-methylaminophenyl	
	III-II =2-methoxy-4-dimethylaminophenyl	
50	III-III =4-amino-5-chloro-2-methoxyphenyl	50
	III-IV =4-amino-2-methoxyphenyl	
	III-V =3-iodo-2-methoxy-4-methylaminophenyl	
	III-VI =5-chloro-2-methoxy-4-dimethylaminophenyl	
	III-VII =2-chloro-4-aminophenyl	
55	III-VIII =3-iodo-4-amino-2-methoxyphenyl	55
	III-IX =2-methoxy-4-methylamino-phenyl	
	III-X =2-chloro-4-nitrophenyl	
	III-XI =4-bromo-2-methoxyphenyl	
	III-XII =3,5-dichlorophenyl	
60	III-XIII =5-chloro-2-methoxy-4-(1-pyrrolyl)phenyl	60
	III-XIV =2-methoxy-4-(1-pyrrolyl)phenyl	

- <sup>1)</sup>hydrogen maleate  
<sup>2)</sup>hydrogen malonate  
<sup>3)</sup>decomposition  
<sup>4)</sup>bis [base] fumarate  
5 <sup>5)</sup>obtained by reduction of corresponding 4-nitro compound 5  
<sup>6)</sup>hydrobromide  
<sup>7)</sup>via imidazolyl intermediate  
<sup>8)</sup>exo form has C-3 H broad multiplet at ca. 5.15 ppm in H<sup>1</sup>N.M.R. endo form has C-3 H double  
triplet at 5.1 ppm. Exo alcohol is eluted before endo isomer on silica gel-eluant CH<sub>2</sub>Cl<sub>2</sub>/5%  
10 CH<sub>3</sub>OH/5% NH<sub>4</sub>OH 10  
<sup>9)</sup>hydrogen oxalate  
<sup>10)</sup>in presence of triethylamine instead of pyridine

#### Example A-1

- 15 **N-(endo-9-methyl-9-aza-bicyclo[3.3.1]non-3-yl)indol-3-yl carboxylic acid amide also called N-(3 $\alpha$ -homotropanyl)-indol-3-yl carboxylic acid amide (process a)** (compound of formula I wherein 15  
A=H in 3 position; R<sub>1</sub>=R<sub>2</sub>=H; X=NH; B=NH; D=IV- $\alpha$  configuration; n=3, R<sub>8</sub>=CH<sub>3</sub>) 15

#### a) Indol-3-yl carboxylic acid chloride

- 32.2 g (0.2 M) dry indol-3-yl carboxylic acid are suspended in 150 ml absolute methylene  
chloride. 26 ml (0.3 M) oxalyl chloride are added to the stirred mixture at 20°C over 30 minutes. Gas  
20 evolution results. The mixture is stirred for 3 1/2 hours at 20°C. 150 ml Hexane are added. The mixture 20  
is stirred for another 20 minutes and the resultant heading compound filtered off, washed with  
methylene chloride/hexane 1:1 dried at 20° in a vacuum to give beige crystals, M.pt. 135—136°  
(decomp) which are used further without purification.

#### b) 9-methyl-9-aza-bicyclo[3.3.1]nonan-3-one oxime (also called 3-homotropanone oxime)

- 25 176 g (2.15 M) sodium acetate and 150 g (2.15 Mol) hydroxylamine hydrochloride are pounded 25  
in a mortar to a thin paste, extracted with 1 litre methanol, the salt filtered off and the solution treated  
with 99.5 g (0.65 M) endo-9-methyl-9-aza-bicyclo[3.3.1]nonan-3-one (3-homotropanone). The oxime  
begins to crystallize after 10 minutes and the mixture is stirred for another 4 hours at 20°C. To work up  
the mixture is concentrated under a vacuum, the residue treated with potassium hydrogen carbonate  
30 solution and extracted with chloroform containing some isopropanol. The combined organic phases are 30  
washed with a little water, dried with sodium sulphate and concentrated to give the heading  
compound. M.pt. 126—127° (from toluene/hexane).

#### c) Endo-9-methyl-9-aza-bicyclo[3.3.1]non-3-yl amine (also called 3 $\alpha$ -amino-homotropane)

- A solution of 50.5 ml (0.95 M) concentrated sulphuric acid in 200 ml absolute tetrahydrofuran  
35 are added to a cooled and stirred mixture of 73 g (1.9 M) lithium aluminium hydride in 900 ml absolute 35  
tetrahydrofuran at -10°C within 2 hours. The mixture is allowed to stand overnight. A solution of 80 g  
(0.475 M) endo-9-methyl-9-aza-bicyclo[3.3.1]nonan-3-one oxime in 1.4 litres absolute  
tetrahydrofuran is added dropwise over 30 minutes to the stirred mixture at 30° and allowed to react  
further at 40° for 3 hours. To work up the reaction mixture is cooled to 10° and a mixture of 150 ml  
40 water in 150 ml tetrahydrofuran is added carefully. The mixture is stirred for an hour at 30°C. 40  
The resultant precipitate is filtered off. The residue is washed with methylene chloride and ether. The  
organic phases are combined and distilled to give the heading compound b.pt. 115—119° (17—18  
Torr)—n<sub>D</sub><sup>20</sup>=1.5066.

- (As will be appreciated the reduction gives mainly the endo product. Analogous reduction of 8-  
45 methyl-8-aza-bicyclo[3.2.1]octan-3-one oxime gives the exo product.) 45

#### d) N-(endo-9-methyl-9-aza-bicyclo[3.3.1]non-3-yl)indol-3-yl carboxylic acid amide

- A solution of 15.4 g (0.1 M) endo-9-methyl-9-aza-bicyclo[3.3.1]non-3-yl amine in 50 ml  
absolute pyridine is added dropwise to a stirred suspension of 14.5 g (0.08 M) indol-3-yl carboxylic  
acid chloride (produced in step a) in 50 ml absolute methylene chloride at -10°C to 0°C.  
50 The resultant yellow suspension is warmed to 20° and stirred overnight. To work up 2N aqueous 50  
sodium carbonate is added. The mixture is extracted several times with methylene chloride and worked  
up in conventional manner. The title compound is obtained after crystallisation three times. M.pt.  
247—249° (decomp.).

#### Example A-2

- 55 **Indol-3-yl carboxylic acid endo-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl ester (process a)** 55  
(Compound of formula I wherein A=H in 3 position; R<sub>1</sub>=R<sub>2</sub>=H; X=NH; B=O; D=IV in  $\alpha$  configuration;  
N=2; R<sub>8</sub>=CH<sub>3</sub>)

6.35 g (45 mM) endo-8-methyl-8-aza-bicyclo[3.2.1]octan-3-ol (Tropine) in 20 ml absolute  
tetrahydrofuran are treated at 0° to 10° with 17 ml of a 2 molar solution of butyl lithium in hexane.



The mixture is stirred for a further 30 minutes. The hexane is removed under a vacuum and replaced by a corresponding amount of tetrahydrofuran to give the lithium salt.

4.8 g (27 mM) of indol-3-yl carboxylic acid chloride in 20 ml tetrahydrofuran are added to the mixture and the beige suspension stirred overnight at 20°C. The mixture is worked up in the usual manner partitioning between methylene chloride and sodium carbonate to give the heading compound in crude form which is chromatographed on silicagel (250 g) eluting the heading compound with methylene chloride containing 10% methanol and 0.5% ammonia. M.pt. 201—202° (methylene chloride/ethyl acetate). M.pt. 283—285° (decomp.)—hydrochloride salt. Methiodide 285—287° (decomposition).

Alternatively indol-3-yl carboxylic acid chloride may be reacted with N,N'-carbonyl di-imidazole to form the imidazolid. This may be reacted with the above lithium salt at 10 to 15° in tetrahydrofuran.

#### Example A-3

**1-methyl-N-(endo-9-methyl-9-aza-bicyclo[3.3.1]non-3-yl)indol-3-yl carboxylic acid amide also called 1-methyl-N-(3 $\alpha$ -homotropanyl)-indol-3-yl carboxylic acid amide (process b) (compound of formula I wherein A=II in 3 position; R<sub>1</sub>=R<sub>2</sub>=H; X=NCH<sub>3</sub>; B=NH; D=IV in  $\alpha$  configuration; n=3; R<sub>8</sub>=CH<sub>3</sub>)**

0.46 g (20 mM) sodium dissolved in 170 ml dry liquid ammonia at -50° are treated dropwise with 1.3 ml (22.5 mM) absolute ethanol diluted with some absolute ether. The resultant colourless suspension of sodium ethanolate is stirred for 15 minutes at -50°. 4.46 g (15 mM) N-(endo-9-methyl-9-aza-bicyclo-[3.3.1]non-3-yl)indol-3-yl carboxylic acid amide are added giving a clear solution. The mixture is stirred for 10 minutes at -50° and 1.25 ml (20 mM) methyl iodide in 4 ml absolute ether is added.

The mixture is stirred at -50° for a further 4 1/2 hours. To work up the ammonia is removed in a vacuum. The residue is partitioned between methylene chloride and water and worked up in the usual manner to give a colourless foam which is chromatographed on 120 g silicagel eluting with methylene chloride containing 5% methanol/3% ammonia the heading compound from the acid. M.pt. 210—212° (recrystallised from ethyl acetate/methanol). M.pt. 295—297° (decomp.)—hydrochloride salt.

The compound may alternatively be produced in analogous manner to Example 1 starting from 1-methyl-indol-3-yl carboxylic acid.

#### Example A-4

**5-fluoro-1-methyl-indol-3-yl carboxylic acid-endo-9-aza-bicyclo[3.3.1]non-3-yl ester also called (N-desmethyl-3 $\alpha$ -homotropanyl)-5-fluoro-1-methyl-indol-3-yl carboxylic acid ester (process c) (compound of formula I; A=II in 3 position; R<sub>1</sub>=5-F; R<sub>2</sub>=H; X=NCH<sub>3</sub>, B=—O—; D=IV in  $\alpha$  configuration; n=3; R<sub>8</sub>=H)**

4.9 g of 5-fluoro-1-methyl-indol-3-yl carboxylic acid endo-9-benzyl-9-aza-bicyclo[3.3.1]non-3-yl ester in 200 ml ethanol are hydrogenated at room temperature and normal pressure in the presence of 1.5 g (10%) palladium on active charcoal catalyst. After 45 minutes the uptake of ca 230 ml hydrogen is finished and the catalyst filtered off. The solvent is removed in a vacuum to give a crystalline residue of the title compound. M.pt. 130—131° (recrystallised from ethanol/little hexane).

#### Example A-5

**2-methoxy-indol-3-yl carboxylic acid (endo-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl) ester also called 2-methoxy-indol-3-yl carboxylic acid tropyl ester (processes d and e) (compound of formula I A=II in 3 position; R<sub>1</sub>=H; R<sub>2</sub>=2-OCH<sub>3</sub>, X=NH; B=O; D=IV in  $\alpha$  configuration; n=2; R<sub>8</sub>=CH<sub>3</sub>)**

5.68 g (20 mM) indol-3-yl carboxylic acid endo-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl ester is added to a stirred suspension of 4 g (30 mM) N-chloro-succinimide in 80 ml absolute chloroform at 20°. The mixture is stirred for 3 hours at 20° to give 2-chloro-indol-3-yl carboxylic acid (endo-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl) ester in a clear yellow solution.

The clear yellow solution is treated with 10 ml absolute methanol and allowed to stand overnight. Usual working up by partitioning the mixture between 1N aqueous sodium carbonate and methylene chloride gave a crude product which is chromatographed on silicagel (30 fold amount) eluting with methylene chloride containing 10% methanol and 0.5% ammonia the title compound, M.pt. 204 to 206° (from ethanol).

#### Example A-6

**3-iodo-indol-4-yl carboxylic acid endo-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl ester (compound of formula I wherein A=II in 4 position, R<sub>1</sub>=H; R<sub>2</sub>=3-I; X=NH; B=—O—; D=IV in  $\alpha$  configuration; n=2; R<sub>8</sub>=CH<sub>3</sub>) (process d)**

A solution of 2.84 g (10 mM) indol-4-yl carboxylic acid endo-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl ester is added dropwise at 15° to a stirred suspension of 2.48 g (11 mM) N-iodo-succinimide in 200 ml absolute chloroform. The mixture is stirred for a further 30 minutes at 20°. Partitioning between 1N sodium carbonate solution and methylene chloride and usual working up gives the

heading compound 163—165° (decomp) (from ethanol). Although the compound may be produced from 3-iodo-indol-4-yl carboxylic acid in analogous manner to that disclosed in Example 2.

#### Example A-7

- 5 **5-chloro-2-methoxy-4-methylamino-benzoic acid 1-aza-bicyclo[2.2.2]oct-3-yl ester also called**  
 5 **5-chloro-2-methoxy-4-methylamino-benzoic acid quinuclidin-3-yl ester** (process a) (compound of  
 formula I wherein A=III; R<sub>4</sub>=OCH<sub>3</sub>; R<sub>5</sub>=H; R<sub>6</sub>=NHCH<sub>3</sub>; R<sub>7</sub>=Cl; B=—O—; D=V in 3 position) 5

##### a) 5-chloro-4-methylamino-2-methoxy-benzoic acid imidazolidine

- 12 g N,N'-carbonyl-diimidazole are added to a stirred solution of 8 g 5-chloro-4-methylamino-2-methoxy-benzoic acid in 300 ml dry tetrahydrofuran at 20 to 25°. The mixture is stirred under  
 10 anhydrous conditions for 1 hour, and the solvent removed at 35 to 40°. The residue is dissolved in  
 methylene chloride. 10

The mixture is washed 2 to 3 times with water, dried over magnesium sulphate, filtered and concentrated. The heading compound crystallises from methylene chloride/hexane. M.pt. 152—154°

##### b) 5-chloro-4-methylamino-2-methoxy-benzoic acid 1-aza-bicyclo[2.2.2]oct-3-yl ester

- 27 ml n-butyl lithium (1.6 Molar) in hexane is added dropwise to a stirred solution of 5.56 g 1-  
 15 aza-bicyclo[2.2.2]octan-3-ol (quinuclidin-3-ol) in 100 ml absolute tetrahydrofuran at 0° to 5° under  
 dry nitrogen. The mixture is stirred for a further 10 to 15 minutes at 0 to 5° and then a solution of 5-  
 chloro-4-methylamino-2-methoxy-benzoic acid imidazolidine in 100 ml absolute tetrahydrofuran is  
 added. It is stirred for an hour. 5 ml saturated aqueous potassium hydrogen carbonate solution is  
 20 added and the solution is decanted. The residue is washed twice with tetrahydrofuran. The combined  
 organic phases are dried over magnesium sulphate, filtered and concentrated. The crude product is  
 treated with an equivalent amount of malonic acid to give the heading compound in hydrogen  
 malonate form. M.pt. 170—172° (from acetone). 20

#### Example A-8

- 25 **4-amino-5-chloro-2-methoxy-benzoic acid exo-8-benzyl-8-aza-bicyclo[3.2.1]oct-3-yl ester also**  
 called **4-amino-5-chloro-2-methoxy-benzoic acid 8-benzyl pseudo-nor-tropyl ester** (process c) 25  
 (compound of formula I wherein A=III; R<sub>4</sub>=OCH<sub>3</sub>; R<sub>5</sub>=H; R<sub>6</sub>=NH<sub>2</sub>; R<sub>7</sub>=Cl; B=O; D=IV in β configuration;  
 n=2; R<sub>8</sub>=benzyl)

##### a) 4-(N-benzyloxycarbonyl)amino-2-methoxy-benzoic acid methyl ester

- A solution of 42.1 g 4-amino-2-methoxy-benzoic acid methyl ester in 600 ml toluene is boiled  
 30 under reflux for 2 1/2 hours together with 60 ml chloroformic phenyl ester. The solution is cooled and  
 crystals of the heading compound filtered off. M.pt. 137—138°. 30

##### b) 4-(N-benzyloxycarbonylamino)-5-chloro-2-methoxy-benzoic acid methyl ester

- 18 g chlorine gas (dried over sulphuric acid) is passed through a stirred solution of 61.4 g 4-(N-  
 35 benzyloxycarbonyl)amino-2-methoxy-benzoic acid methyl ester in 1 litre chloroform at 20° for 20 to  
 25 minutes. The reaction mixture is concentrated under a vacuum to give the crystals of the heading  
 compound which is reacted further as such. 35

##### c) 4-(N-benzyloxycarbonylamino)-5-chloro-2-methoxy-benzoic acid

- 200 ml 2N aqueous sodium hydroxide solution is added dropwise to a stirred solution of 72.1 g  
 40 of the benzoic acid methyl ester produced in step b) in 800 ml dioxane. The mixture is stirred for 20  
 hours and the organic solvent removed under a vacuum. The residue is dissolved in water and adjusted  
 to pH 5—6 with 3N hydrochloric acid. The heading compound is filtered off and washed with water.  
 M.pt. 182—183° (from methanol). 40

##### d) 4-(N-benzyloxycarbonylamino)-5-chloro-2-methoxy-benzoic acid imidazolidine

- The compound is produced in analogous manner to Example A-7a. 45

##### e) 4-(N-benzyloxycarbonylamino)-5-chloro-2-methoxy-benzoic acid exo-8-benzyl-8-aza-bicyclo[3.2.1]oct-3-yl ester

The compound is produced in analogous manner to Example A-7b.

##### f) 4-amino-5-chloro-2-methoxy-benzoic acid exo-8-benzyl-8-aza-bicyclo[3.2.1]oct-3-yl ester

- 5.4 g 4-(N-benzyloxycarbonylamino)-5-chloro-2-methoxy-benzoic acid exo-8-benzyl-8-aza-  
 50 bicyclo[3.2.1]oct-3-yl ester in 100 ml ethanol are hydrogenated in the presence of 0.7 g palladium  
 (10%) on charcoal for 50 minutes at atmospheric pressure taking up one equivalent of hydrogen. The  
 mixture is filtered through a filtering aid (Hyflo Supercell) and the filtrate concentrated. The residue is  
 chromatographed on silicagel with methylene chloride containing 5% methanol and the heading  
 55 compound obtained in free base form. M.pt. 241—242° (hydrobromide produced from HBr, in  
 ethanol). 55

**Example A-9**

**4-amino-5-chloro-2-methoxy-benzoic acid exo-8-aza-bicyclo[3.2.1]oct-3-yl ester also called 4-amino-5-chloro-2-methoxy-benzoic acid pseudo nor-tropyl ester** (process c) (compound of formula I wherein A=III; R<sub>4</sub>=OCH<sub>3</sub>; R<sub>5</sub>=H; R<sub>6</sub>=NH<sub>2</sub>; R<sub>7</sub>=Cl; B=O; D=IV in β configuration; n=2; R<sub>8</sub>=H)

- 5 8.4 g 4-(N-benzyloxycarbonylamino)-5-chloro-2-methoxy-benzoic acid exo-8-benzyl-8-bicyclo[3.2.1]oct-3-yl ester in 250 ml ethyl acetate or acetic acid are hydrogenated in the presence of 1.2 g 10% palladium on charcoal at atmospheric pressure and at 20 to 25° for 2 hours. The mixture is filtered (e.g. through Hyflo), the filtrate is evaporated and the residue dissolved in methylene chloride.
- The organic phase is washed with 1N sodium hydroxide and then with water, dried over
- 10 magnesium sulphate and concentrated. The product is chromatographed through silicagel using methylene chloride +5% methanol and methylene chloride+20% methanol. The title compound is crystallised as the hydrochloride. M.pt. 258—259° (from ethanol).

**Example A-10**

- 15 **Indol-4-ylcarboxylic acid endo-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl ester also called indol-4-yl carboxylic acid tropyl ester** (compound of formula I A=II in 4 position; R<sub>1</sub>=R<sub>2</sub>=H; R<sub>3</sub>=NH; B=O; D=IV in α configuration; n=2; R<sub>8</sub>=CH<sub>3</sub>)

- 7 g (50 mM) endo-8-methyl-8-aza-bicyclo[3.2.1]octan-3-ol (tropine) in 15 ml absolute tetrahydrofuran is treated at 10 to 15° dropwise with 20 ml (40 mM) of 2 Molar Butyl lithium in hexane. The mixture is stirred for 30 minutes at 20°, and then concentrated to a volume of about 10
- 20 ml to remove the hexane to give the lithium enolate. 10 ml tetrahydrofuran is added.

- 4.8 g (30 mM) dry indol-4-yl carboxylic acid in 15 ml absolute tetrahydrofuran is treated portionwise with 5.85 g (36 mM) N,N'-carbonyl-diimidazole. The mixture is allowed to stand for 90 minutes at 20° and then is added dropwise to the lithium enolate. The resultant suspension is stirred overnight at 20°C, and partitioned between methylene chloride/a little isopropanol and 1N sodium carbonate. The organic phases are washed and dried over sodium sulphate to give on evaporation the
- 25 heading compound.

M.pt. 220—222° (decomp) (from ethanol).

**Example A-11**

- 30 **Indol-4-yl carboxylic acid endo-9-methyl-9-aza-bicyclo[3.3.1]non-3-yl ester also called 3α-homotropanyl indol-4-yl carboxylic ester** (compound of formula I A=II in 4 position; X=NH; R<sub>1</sub>=R<sub>2</sub>=H; R<sub>3</sub>=NH; B=O; D=IV in α configuration; n=3; R<sub>8</sub>=CH<sub>3</sub>) (process a)

- a) 7.65 g (50 mM) endo-9-methyl-9-aza-bicyclo[3.3.1]nonan-3-ol in 15 ml absolute tetrahydrofuran are treated dropwise at 10 to 15° with 20 ml (40 mM) 2 Molar Butyl lithium hexane solution. The resultant mixture is stirred for 30 minutes at 20°. The hexane is then evaporated and
- 35 replaced by tetrahydrofuran to give a solution of the lithium salt.

- b) 4.8 g (30 mM) dry indol-4-yl carboxylic acid in 15 ml absolute tetrahydrofuran is treated portionwise at room temperature with 5.85 g (36 mM) N,N'-carbonyl-diimidazole. After gas evolution finishes the solution is stood for 90 minutes at 20° and then treated dropwise with the above lithium salt at 10 to 15°. The resultant suspension is stirred for 15 hours at 20° and partitioned between
- 40 methylene chloride/little isopropanol and 1N sodium carbonate solution. The organic phase is washed with water, dried with sodium sulphate and evaporated to give the heading compound. M.pt. 189—190° (from ethanol).

**B Series Examples**

The following compounds of formula I wherein D is a compound of formula IV are produced:—

45	Example	A	B	n	R <sub>8</sub>	Conf.	M.pt.	Prep.	45
	B-1	5-chloro-indol-3-yl	O	2	CH <sub>3</sub>	endo	235—237 <sup>o3)</sup>	2	
	B-2	4-methoxy-indol-3-yl	O	2	CH <sub>3</sub>	endo	193—194°	2	
	B-3	5-methoxy-indol-3-yl	O	2	CH <sub>3</sub>	endo	214—216°	2	
	B-4	1-methyl-indol-3-yl	O	2	CH <sub>3</sub>	endo	143—144°	3	
50	B-5	indol-3-yl	O	2	CH <sub>3</sub>	exo	239—240 <sup>o3)</sup>	2	50
	B-6	indol-3-yl	O	3	CH <sub>3</sub>	endo	208—209 <sup>o3)</sup>	2	
	B-7	indol-3-yl	O	2	n-C <sub>3</sub> H <sub>7</sub>	endo	158—159°	2	
	B-8	indol-3-yl	O	2	benzyl	exo	164—165 <sup>o8)</sup>	2	
	B-9	indol-3-yl	O	2	benzyl	endo	162—163 <sup>o8)</sup>	2	
55	B-10	indol-3-yl	O	2	H	endo	261—263 <sup>o3)</sup>	8f	55
	B-11	5-fluoro-indol-3-yl	O	3	H	endo	247—248 <sup>o3)</sup>	4	
	B-12	1-methyl-indol-3-yl	O	3	H	endo	147—148°	4	
	B-13	indol-3-yl	O	3	H	endo	234—235 <sup>o3)</sup>	4	
	B-14	5-methyl-indol-3-yl	O	3	CH <sub>3</sub>	endo	228—230°	2	
60	B-15	2-methyl-indol-3-yl	O	3	CH <sub>3</sub>	endo	204—205°	2	60

**B Series Examples (Cont.)**

B Series Examples (Cont.)								
Example	A	B	n	R <sub>8</sub>	Conf.	M.pt.	Prep.	
5	B-16	5-fluoro-1-methylindol-3-yl	O	3	CH <sub>3</sub>	endo	107—108°	3 or 2
	B-17	5-fluoro-indol-3-yl	O	3	CH <sub>3</sub>	endo	244—245° <sup>3)</sup>	2
	B-18	5-fluoro-1-methyl indol-3-yl	O	3	benzyl	endo	127—128°	3
	B-19	1-methyl-indol-3-yl	O	3	CH <sub>3</sub>	endo	103—104°	3
	B-20	5-methyl-indol-3-yl	NH	3	CH <sub>3</sub>	endo	265—267° <sup>3)</sup>	1
10	B-21	5-fluoro-indol-3-yl	NH	2	CH <sub>3</sub>	endo	220—222°	1
	B-22	1-methyl-indol-3-yl	NH	2	CH <sub>3</sub>	endo	169—170°	3 or 1
	B-23	2-methyl-indol-3-yl	NH	2	CH <sub>3</sub>	endo	196—197° <sup>3)</sup>	1
	B-24	indol-3-yl	NH	2	CH <sub>3</sub>	exo	261—262° <sup>3)</sup>	1
	B-25	indol-3-yl	NH	2	CH <sub>3</sub>	endo	205—206°	1
15	B-26	5-chloro-indol-3-yl	NH	2	CH <sub>3</sub>	endo	210—212°	1
	B-27	indol-3-yl	O	3	benzyl	endo	234—235°	1
	B-28	1-methyl-indol-3-yl	O	3	benzyl	endo	147—148°	2
	B-29	5-fluoro-indol-3-yl	O	3	benzyl	endo	193—194°	2
	B-30	benzothien-3-yl	O	3	CH <sub>3</sub>	endo	129—130°	2
20	B-31	benzothien-3-yl	NH	3	CH <sub>3</sub>	endo	225—226°	1 <sup>7)</sup>
	B-32	benzofuran-3-yl	NH	3	CH <sub>3</sub>	endo	199—201°	1
	B-33	benzfuran-3-yl	O	3	CH <sub>3</sub>	endo	77—78°	2
	B-34	1(H)inden-3-yl	NH	3	CH <sub>3</sub>	endo	181—183°	1
	B-35	indol-3-yl	NH	4	CH <sub>3</sub>	exo	264—266° <sup>3)</sup>	1 <sup>10)</sup>
	B-36	indol-3-yl	O	4	CH <sub>3</sub>	exo	264—267° <sup>3)</sup>	2

**C Series Examples**

25 The following compounds of formula I wherein D is a group of formula IV are produced:— 25

Example		A	B	n	R <sub>8</sub>	Conf.	M.pt.	Prep.
30	C-1	indol-5-yl	O	2	CH <sub>3</sub>	endo	191—193°	2
	C-2	indol-5-yl	O	3	CH <sub>3</sub>	endo	148—149°	10
	C-3	3-iodo-indol-5-yl	O	3	CH <sub>3</sub>	endo	172—174°	6
	C-4	indol-4-yl	NH	2	CH <sub>3</sub>	exo	267—269° <sup>3)</sup>	1
	C-5	indol-4-yl	NH	2	CH <sub>3</sub>	endo	221—223° <sup>3)</sup>	1
	C-6	indol-5-yl	NH	2	CH <sub>3</sub>	endo	220—221°	1

**D Series Examples**

35 in analogous manner to that described above the following compounds wherein A is a group of formula III and D is a group of formula IV are produced:— 35

	Example	A	B	n	R <sub>8</sub>	Conf.	M.pt.	Prep.	
40	D-1	III-I	O	2	CH <sub>3</sub>	endo	193—195 <sup>o 1)</sup>	7	40
	D-2	III-II	O	2	benzyl	exo	112—114 <sup>o 2)</sup>	7	
	D-3	III-III	O	2	CH <sub>3</sub>	endo	154—155 <sup>o 2)</sup>	7	
	D-4	III-III	O	2	H	endo	168—169 <sup>o 2)</sup>	9	
	D-5	III-IV	O	2	H	endo	184—185 <sup>o 1)</sup>	9	
	D-6	III-IV	O	2	H	exo	166—167 <sup>o 2)</sup>	9	
	D-7	III-IV	O	2	CH <sub>3</sub>	endo	245—246 <sup>o 4)</sup>	7	
45	D-8	III-VI	O	2	CH <sub>3</sub>	endo	146—147 <sup>o 2)</sup>	7	45
	D-9	III-VII	O	2	CH <sub>3</sub>	endo	210—211 <sup>o 5)</sup>	7	
	D-10	III-VIII	O	2	CH <sub>3</sub>	endo	216 <sup>o 6)</sup>	7	
	D-11	III-V	O	3	CH <sub>3</sub>	endo	164—166 <sup>o</sup>	7	
50	D-12	III-IX	O	3	CH <sub>3</sub>	endo	163—164 <sup>o</sup>	7	50
	D-13	III-X	O	2	CH <sub>3</sub>	endo	132—133 <sup>o</sup>	7	
	D-14	III-XI	O	2	CH <sub>3</sub>	endo	91—92 <sup>o</sup>	7	
	D-15	III-XII	O	3	CH <sub>3</sub>	endo	170—171 <sup>o</sup>	7	
	D-16	III-XIII	O	2	CH <sub>3</sub>	endo	158—159 <sup>o 2)</sup>	7	
	D-17	III-XIV	O	2	CH <sub>3</sub>	endo	159—160 <sup>o 2)</sup>	7	

**F Series Examples**

The following compounds of formula I wherein A is a group of formula II or III and D is a group of formula V, are produced:—

	Example	A	B	D substit-	M.pt.	Prep.	
5	E-1	indol-3-yl	O	3	219—221 <sup>o(4)31</sup>	7	5
	E-2	III-I	NH	3	145—147 <sup>o</sup>	7*	
					154—156 <sup>o(2)</sup>	7	
	E-3	III-XII	O	3	159—160 <sup>o</sup>	7	

\*if desired in boiling ethanol

10	Representative starting materials of formula VII							10
Example	n	R <sub>8</sub>	Conf.	B	Characterisation	Trivial name		
15	a)	2	CH <sub>3</sub>	endo	O	m.pt. 59—61°	Tropine	15
	b)	2	CH <sub>3</sub>	exo	O	m.pt. 105—107°	Pseudotropine	
	c)	2	CH <sub>3</sub>	endo	NH	bpt 82°/12 mm	Tropinamine	
	d)	2	CH <sub>3</sub>	exo	NH	bpt 75°/0.05 mm	Pseudotropinamine	
	e)	3	CH <sub>3</sub>	endo	NH	bpt 115/17 mm		
	f)	3	CH <sub>3</sub>	endo	OH	amorphous <sup>+</sup>		
	g)	3	benzyl	endo	OH	m.pt. 69—70° <sup>+</sup>		
	h)	2	n-C <sub>3</sub> H <sub>7</sub>	endo	OH	oil <sup>++</sup>		

20	<sup>+</sup> prepared by reduction of ketone by NaBH <sub>4</sub> with separation of isomers	20
	<sup>++</sup> prepared by reduction of ketone by NaBH <sub>4</sub> . Major product.	

**i) N-methyl-10-aza-bicyclo[4.3.1]dec-8-ylamine (for Example B-35)**

25	15 g of sodium are reacted in analogous manner to that disclosed below in Example j) with 9.69 g 10-methyl-10-azabicyclo[4.3.1]decan-8-one oxime acetate [m.pt. 253—253.5°C prepared in analogous manner to that disclosed in Example A-1b) giving an oil bpt 105°/0.9 mm after working up in conventional manner.	25
----	--	----

30	<sup>1</sup> H.N.M.R. (200 MHz) 3.27—3.04 (multiplet, 2H, HC-(1)- and H-C(6)); 2.59 (singlet, 3H, H-C(11)), 2.01—1.49 (multiplet, 13H 6×2H-C and H-C(8)); 1.24 (singlet, 2H; 2.H-N exchangeable with D <sub>2</sub> O); <sup>13</sup> C N.M.R. (25.2 MHz) 56.41 (d) doublet, 42.85 (quartet C-11), 41.44 (doublet), 37.13 (triplet, C-7 and C-9), 32.54 (triplet, C-2 and C-5) and 24.88 (triplet C-3 and C-4). The configuration is believed to be exo.	30
----	--	----

**j) N-methyl-10-azabicyclo[4.3.1]decan-8-ol (for Example B-36)**

35	5 g sodium pieces are added to a hot solution of 3.5 g 8-methyl-10-azabicyclo[4.3.1]decan-8-one in 100 ml of dry n-butanol. The mixture is refluxed for an hour, cooled and acidified with concentrated hydrochloric acid to pH 2. The mixture is evaporated to dryness to give a residue which is taken up in sodium hydroxide. The mixture is extracted with chloroform, dried and distilled, b.pt. 90—95°/0.025 mm.	35
----	--	----

40	<sup>1</sup> H.N.M.R. (200 MHz) 4.07—4.23 (multiplet, <sup>1</sup> H-C-(8) half width ca 20 Hz); 3.63—3.69 (triplet, 0.33 H, j=7 Hz, HO-C-(8) one isomer exchangeable with D <sub>2</sub> O), 2.13—1.38 (multiplet, 12H, 6×CH <sub>2</sub> ). <sup>13</sup> C.N.M.R. (25.2 MHz) 63.10 (doublet C-8), 56.80 (doublet, C-1 and C-6), 43.13 (quartet, NCH <sub>3</sub> ), 36.30 (triplet-C-7 and C-9), 34.80 (triplet, C-2 and C-5), 25.04 (triplet C-3 and C-4). The configuration is believed to be exo.	40
----	---	----

The compounds of the invention exhibit pharmacological activity and are therefore useful as pharmaceuticals, e.g. for therapy.

45	In particular the compounds exhibit serotonin M receptor antagonist activity as indicated in standard tests. For example, in one test the action of the compounds in inhibiting the action of serotonin in reducing the amplitude of the compound action potential from the isolated rabbit vagus nerve was observed according to the principles of Riccioppo Neto, European Journal of Pharmacology (1978) 49 351—356, under conditions permitting differentiation between action potentials generated in myelinated nerve fibres (A fibres) and those generated in small non-myelinated fibres (C fibres) as described by B. Oakley and R. Schater, Experimental Neurobiology, A Laboratory Manual, University of Michigan Press, 1978, p. 85 to 96. Serotonin itself exerts its effect selectively on the C fibres and reduces the amplitude of the action potential in these fibres progressively with dosage. This action of serotonin is not blocked by the known serotonin antagonists, metitepine, methylsergide, BOL-148, which have been said to block D receptors for serotonin, but not M receptors (see Gaddam and Picarelli, Brit. J. Pharmacol. (1957), 12, 323—328). It therefore appears that serotonin reduces the amplitude of the action potential carried by the C fibres through an effect mediated by M receptors for serotonin which are located on these nerve fibres.	45
50		50
55		55

- The test may be effected by establishing a dose response curve for serotonin ( $10^{-7}$ — $5 \times 10^{-8}$  M) after setting up the nerve. The serotonin is washed out and when the C fibre action potential has regained its original amplitude the compound of the invention at a set concentration of from about  $10^{-16}$  M to about  $10^{-8}$  M is preincubated with the nerve for 30 to 60 minutes. Varying concentrations of serotonin ( $10^{-7}$  to  $10^{-4}$  M) are then applied with the compound of the invention at the concentration as was present during the preincubation period. 5
- The M receptor antagonists of the invention either entirely block the action of serotonin (non-competitive antagonist) or cause a parallel shift of the serotonin/dose response curve to the right (i.e. increased concentrations of serotonin were required for effect) (competitive antagonist). The  $pD'_2$  or  $pA_2$  value may be obtained in the conventional manner. 10
- The serotonin M receptor antagonist activity is also indicated by inhibiting the effect of serotonin on the isolated rabbit heart according to the method of J. R. Fozard and A. T. Mobarak Ali, European Journal of Pharmacology, (1978) 49, 109—112 at concentrations of  $10^{-11}$  to  $10^{-8}$  M of the compound of the invention.  $pD'_2$  or  $pA_2$  values may be calculated in the conventional manner. 15
- The action of the compounds as serotonin M receptor antagonists for the treatment of analgesia is confirmed by action in the hot plate test at a dose of from about 0.1 to 100 mg/kg s.c. or p.o. 15
- The serotonin M receptor antagonist activity is furthermore indicated in the cantharidine blister base test at a concentration of about  $10^{-8}$  M. A blister is produced on the skin of the forearm of human volunteers with cantharidine. When serotonin is applied to the base of such blisters it produces pain 20 which can be measured, the intensity being proportional to the concentration of serotonin applied. The procedure has been described by C. A. Keele and D. Armstrong in Substances producing Pain and Itch, Edward Arnold, London, 1964, p. 30 to 57. This algesic action of serotonin is not inhibited by the serotonin D receptor antagonists such as lysergic acid diethylamide or its bromo derivative and is therefore believed to be mediated by M receptors. 20
- In the procedure followed the area under the curve instead of the peak amplitude is measured by a linear integrator coupled to a pain intensity indicator which is operated by the volunteer. With increasing concentrations of serotonin a cumulative dose-response curve to serotonin may be obtained. When no further response on increasing the serotonin concentration is obtained, the serotonin is washed off and the blister incubated with physiological buffer solution for at least 40 25 minutes before the compound of the invention, e.g. the preferred compounds of Examples A-2 or A-3, is applied. The test substance is preincubated with the blister base for 30 minutes at a concentration of about  $10^{-8}$  M before varying concentrations of serotonin are applied. A  $pA_2$  value may be obtained in the conventional manner. 30
- The compounds of the invention are therefore indicated for use as serotonin M receptor antagonists e.g. for the treatment of pain, especially migraine, vascular and cluster headaches and trigeminal neuralgia and also for the treatment of heart circulation disorders, e.g. for the treatment of sudden death, and possibly as anti-psychotics. 35
- An indicated daily dose is from about 0.5 to 500 mg conveniently administered in divided doses in unit dosage form 2 to 4 times a day containing from about 0.2 to about 250 mg of the compound or 40 in sustained release form.
- The compounds of the invention furthermore exhibit anti-arrhythmic activity as indicated by their serotonin M receptor antagonist activity and in standard tests. For example the compounds inhibit arrhythmias induced by norepinephrine in anaesthetized rats. In this test infusions of norepinephrine (3 to 10 microgram/animal body weight) are given until an arrhythmic phase as indicated by ECG 45 measurements lasts longer than 10 seconds duration. After control of 3 consecutive injections of norepinephrine the compound of the invention is injected at from about 10 to about 500 microgram/kg animal body weight followed by norepinephrine injections. The arrhythmic phase is reduced, or abolished depending on the dose of test compound. 45
- The compounds are therefore indicated for use as anti-arrhythmic agents. An indicated daily dose is from about 0.5 to about 500 mg conveniently administered orally or by injection in divided doses 2 to 4 50 times a day or in unit dosage form containing from about 0.2 to about 250 mg, or in sustained release form.
- The present invention accordingly provides a compound of the invention in pharmaceutically acceptable form, e.g. in free base form, or pharmaceutically acceptable acid addition salt form or 55 quaternary ammonium salt form, for use as a pharmaceutical, particularly for use as a serotonin M antagonist for those diseases where blockage of serotonin M receptors would be expected to have beneficial effects, e.g. as an analgesic agent, especially as an anti-migraine agent and as an anti-arrhythmic agent. 55
- The preferred indication is the analgesic indication. The preferred compounds are the title compounds of Examples A2 and A3. 60
- The compounds of the invention may be administered in free base form, or in pharmaceutically acceptable salt form, e.g. suitable acid addition salts and quaternary ammonium salts. Such salts exhibit the same order of activity as the free bases. The present invention accordingly also provides a pharmaceutical composition comprising a compound of the invention, in particular a compound of 65 formula I, an acid addition salt thereof or a quaternary ammonium salt thereof, in association with a 65

pharmaceutical carrier or diluent. Such compositions may be formulated in conventional manner so as to be for example a solution or a tablet.

- A group of compounds comprises compounds of formula I wherein A is a group of formula II, wherein  $R_1$  and  $R_2$  independently are hydrogen, halogen,  $(C_{1-4})$ alkyl, or  $(C_{1-4})$ alkoxy,  $R_2$  is in the 4 or 5 positions,  $R_3$  is hydrogen or  $(C_{1-4})$ alkyl, the free valence is in position 3, 4 or 5; a group of formula III wherein  $R_4$  is hydrogen, halogen or  $(C_{1-4})$ alkoxy;  $R_5$  is hydrogen or halogen;  $R_6$  is amino, nitro,  $(C_{1-4})$ alkylamino, di- $(C_{1-4})$ alkyl-amino or halogen, or 1-pyrrolyl;  $R_7$  is hydrogen or halogen; D is a group of formula IV wherein  $R_8$  is hydrogen,  $(C_{1-4})$ alkyl or benzyl or a group of formula V wherein the free valence is attached to the 3 position and subject to the above proviso to formula I.
- A group of compounds comprises the compounds of the above formula I excluding any one of the specific examples e.g. the compound of Examples A2 or A3.


#### Claims

1. A process for the production of a di-carbocyclic or heterocyclic carboxylic acid alkylene bridged piperidyl ester or amide or a substituted benzoic acid alkylene bridged piperidyl ester or amide, with the provisos that
  - a) any benzoic acid ester having the alkylene bridge between two ring piperidyl carbon atoms is substituted in the phenyl ring at least one of the ortho or meta positions,
  - b) any benzoic acid ester unsubstituted in both the ortho positions, or having halogen or alkyl in at least one of the ortho positions and only hydrogen or halogen in the meta and para positions, and having the alkylene bridge between two ring piperidyl carbon atoms, has a minimum of 3 carbon atoms in the alkylene bridge,
  - c) any benzoic acid ester having an alkylene bridge between the piperidyl nitrogen atom and a ring carbon atom and having an oxy substituent has either at least one substituent other than an oxy substituent or has only 2 oxy substituents in the benzoic acid nucleus,
  - d) any monocyclic heterocyclic carboxylic acid amide or ester the heterocycle of which is a six membered ring containing ring nitrogen atoms or a heterocyclic carboxylic acid amide the heterocyclic of which contains two oxygen atoms, has an alkylene bridge between the piperidyl nitrogen atom and a ring carbon atom,
  - e) any benzoic acid amide has the alkylene bridge bound between the ring piperidyl nitrogen atom and a ring carbon atom,
  - f) any benzoic acid amide does not have alkyl or hydroxy or halogen substituents in any of the ortho positions, and
  - g) thenoyl and naphthoyl 8-aza-bicyclo[3.2.1]oct-3-yl esters are excluded, as well as acid addition salts and quaternary ammonium salts thereof,
- which includes the step of condensing an appropriate di-carbocyclic or heterocyclic carboxylic acid or benzoic acid or a reactive acid derivative thereof, or a precursor of the acid or derivative, with an appropriate alkylene bridge piperidyl amine or piperidinol, or a precursor thereof, and as necessary converting the resultant piperidyl ester or amide, or acid addition salt or quaternary ammonium salt thereof into the required piperidyl ester or amide or acid addition salt or quaternary ammonium salt thereof and recovering the resultant piperidyl ester or amide as such or as an acid addition salt or as a quaternary ammonium salt thereof.

2. A process for the production of a compound of formula I

wherein A is a group of formula II

45



II


45

wherein

- the free valence is attached to either fused ring,  
 X is  $-CH_2-$ ,  $-NR_3-$ ,  $-O-$ , or  $-S-$ ,  
 $R_1$  and  $R_2$  independently are hydrogen, halogen  $(C_{1-4})$ alkyl,  $(C_{1-4})$ alkoxy, hydroxy, amino,  $(C_{1-4})$ alkylamino, di- $(C_{1-4})$ alkylamino, mercapto or  $(C_{1-4})$ alkylthio,  
 $R_3$  is hydrogen  $(C_{1-4})$ alkyl,  $(C_{3-6})$ alkenyl, aryl or aralkyl, or a group of formula III

50

50



III


wherein

$R_4$  to  $R_7$ , independently are hydrogen, amino, nitro,  $(C_{1-4})$ alkylamino, di $(C_{1-4})$ alkylamino, halogen,  $(C_{1-4})$ alkoxy,  $(C_{1-4})$ alkyl,  $(C_{1-4})$ alkanoylamino or pyrrolyl, with the proviso that at least one of  $R_4$  and  $R_5$  is other than hydrogen,

5 B is  $—O—$  or  $—NH—$ , or

D is group of formula IV

5




IV

wherein

$n$  is 2, 3 or 4,

10  $R_8$  is hydrogen,  $(C_{1-7})$ alkyl,  $(C_{3-5})$ alkenyl, or aralkyl, or a group of formula V

10



V

with the further provisos (i) that when A is a group of formula III, and B is  $—NH—$ , then D is a group of formula V, (ii) that when A is a group of formula III wherein either  $R_4$  is hydrogen, or wherein  $R_4$  is halogen or alkyl and  $R_5$  to  $R_7$  are chosen from halogen or hydrogen, and B is  $—O—$  and D is a group of formula IV, then  $n$  is 3 or 4, (iii) that when A is a group of formula III and one of  $R_4$  to  $R_7$  is alkoxy, and D is a group of formula V then either one of the others of  $R_4$  to  $R_7$  is other than hydrogen or alkoxy or only two of  $R_4$  to  $R_7$  are alkoxy,

15 v) that when A is a group of formula III wherein  $R_4$  is alkyl or halogen, then B is  $—O—$ , as well as acid addition salts and quaternary ammonium salts thereof,

15

20 which includes the step of

20

a) condensing an appropriate compound of formula VI



VI

wherein

25 A is as defined above, or a reactive derivative thereof, or a precursor of the acid or derivative, with an appropriate compound of formula VII

25



VII

30 wherein B and D are as defined above, or a precursor of the compound, or

30

b) alkylating a compound of formula I having a secondary amino group to produce a compound of formula I with a tertiary amino group,

c) deprotecting any protected form of a compound of formula I to obtain a compound of formula I,

35 d) halogenating a compound of formula I wherein A is a group of formula II and  $R_2$  is hydrogen to obtain the corresponding compound wherein  $R_2$  is halogen, or

35

e) alkoxyating a compound of formula I wherein A is a group of formula II and  $R_2$  is halogen to obtain the corresponding compound wherein  $R_2$  is alkoxy, and

40 recovering the resultant compound of formula I as such or as an acid addition salt or as a quaternary ammonium salt thereof.

40

3. A process for the production of a di-carbocyclic or heterocyclic or substituted benzoic acid ester or amide as defined in claim 1, or an acid addition salt or quaternary ammonium salt of the ester or amide substantially as hereinbefore described with reference to any one of the examples.

4. A dicarbocyclic or heterocyclic or substituted benzoic acid ester or amide or an acid addition salt or quaternary salt of the ester or amide whenever prepared according to the process of claim 1, 2 or 3.

45

5. A di-carbocyclic or heterocyclic carboxylic acid alkylene bridged piperidyl ester or amide or a substituted benzoic acid alkylene bridged piperidyl ester or amide, with the provisos that


50 a) any benzoic acid ester having the alkylene bridge between two ring piperidyl carbon atoms is substituted in the phenyl ring at least one of the ortho or meta positions,

50

b) any benzoic acid ester unsubstituted in both the ortho positions, or having halogen or alkyl in at least one of the ortho positions and only hydrogen or halogen in the meta and para positions, and having the alkylene bridge between two ring piperidyl carbon atoms, has a minimum of 3 carbon atoms, in the alkylene bridge,




- c) any benzoic acid ester having an alkylene bridge between the piperidyl nitrogen atom and a ring carbon atom and having an oxy substituent has either at least one substituent other than an oxy substituent or has only 2 oxy substituents in the benzoic acid nucleus,
- d) any monocyclic heterocyclic carboxylic acid amide or ester the heterocycle of which is a six membered ring containing ring nitrogen atoms or a heterocyclic carboxylic acid amide the heterocycle of which contains two oxygen atoms, has an alkylene bridge between the piperidyl nitrogen atom and a ring carbon atom, and
- e) any benzoic acid amide has the alkylene bridge bound between the ring piperidyl nitrogen atom and a ring carbon atom, and
- f) any benzoic acid amide does not have alkyl or hydroxy or halogen substituents in the ortho position, and
- g) thenoyl and naphthoyl 8-aza-bicyclo[3.2.1]oct-3-yl esters are excluded, as well as acid addition salts and quaternary ammonium salts thereof.
6. A compound of formula I as defined in claim 2, as well as acid addition salts thereof and quaternary ammonium salts thereof.
7. A compound of claim 6 wherein aryl is unsubstituted phenyl or phenyl mono- or poly-substituted by (C<sub>1-4</sub>)alkyl, halogen, hydroxy or (C<sub>1-4</sub>)alkoxy, and wherein aralkyl is (C<sub>1-4</sub>)alkyl substituted by unsubstituted phenyl or phenyl mono- or poly-substituted by (C<sub>1-4</sub>)alkyl, halogen, hydroxy or (C<sub>1-4</sub>)alkoxy, as well as acid addition salts and quaternary ammonium salts thereof.
8. A compound of claim 6 which is a compound of formula Ipa



Ipa

wherein


- R<sub>4pa</sub> is halogen, (C<sub>1-4</sub>)alkylamino, or (C<sub>1-4</sub>)alkoxy,
- R<sub>5pa</sub> is hydrogen,
- R<sub>6pa</sub> is amino, (C<sub>1-4</sub>)alkylamino, or di(C<sub>1-4</sub>)alkylamino,
- R<sub>7pa</sub> is hydrogen or fluorine, chlorine or bromine and
- R<sub>8pa</sub> is hydrogen, (C<sub>1-7</sub>)alkyl or aralkyl,
- as well as acid addition salts and quaternary ammonium salts thereof.
9. A compound of claim 6 which is a compound of formula Ipb



Ipb

wherein

- R<sub>4pa</sub>, R<sub>5pa</sub>, R<sub>6pa</sub> and R<sub>8pa</sub> are as defined in claim 8, and
- R<sub>7pb</sub> is hydrogen or halogen,
- as well as acid addition salts and quaternary ammonium salts thereof.
10. A compound of claim 6 which is a compound of formula Iqa



Iqa

wherein


the free valence is attached to either fused ring, and  
n' is 2 or 3, and

R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub> and R<sub>8</sub> are as defined in claim 6,

5 as well as acid addition salts and quaternary ammonium salts thereof.

5

11. A compound of claim 6 which is a compound of formula lqb



wherein

the free valence is attached to either fused ring, and

10 R<sub>1qb</sub> and R<sub>2qb</sub> are independently hydrogen, halogen, or (C<sub>1-4</sub>)alkyl,

10

R<sub>3qb</sub> is hydrogen or (C<sub>1-4</sub>)alkyl,


R<sub>8qb</sub> is hydrogen, (C<sub>1-7</sub>) alkyl or aralkyl, and

n' is 2 or 3,

as well as acid addition salts and quaternary ammonium salts thereof.

15 12. A compound of claim 6 of formula lqc

15




wherein

the carbonyl group is attached to either fused ring, and

20 R<sub>2qc</sub> is as R<sub>2</sub> defined in claim 2 other than (C<sub>1-4</sub>)alkoxy and hydroxy, and  
n', R<sub>1</sub>, R<sub>3</sub>, R<sub>7</sub> are as defined in claim 6 or 11 as well as acid addition salts and quaternary  
ammonium salts thereof.

20


13. A compound of claim 6 of formula lsa



wherein R<sub>4pa</sub>, R<sub>5pa</sub>, R<sub>6pa</sub> and R<sub>7pb</sub> are as defined in claim 9, as well as acid addition salts and quaternary  
25 ammonium salts thereof.

25

14. A compound of claim 6 of the formula lsb



wherein R<sub>4pa</sub>, R<sub>5pa</sub>, R<sub>6pa</sub> and R<sub>7pb</sub> are as defined in claim 9, as well as acid addition salts and quaternary  
ammonium salts thereof.

15. A compound of claim 6 wherein A is a group of formula II, wherein R<sub>1</sub> and R<sub>2</sub> independently are hydrogen, halogen, (C<sub>1-4</sub>)alkyl, or (C<sub>1-4</sub>)alkoxy, R<sub>3</sub> is in the 4 or 5 positions, R<sub>3</sub> is hydrogen or (C<sub>1-4</sub>)alkyl, and the free valence is in position 3, 4 or 5, or a group of formula III wherein R<sub>4</sub> is halogen or (C<sub>1-4</sub>)alkoxy, R<sub>5</sub> is hydrogen or halogen, R<sub>6</sub> is amino, nitro, (C<sub>1-4</sub>)alkylamino, or di(C<sub>1-4</sub>)alkylamino, 5  
halogen or 1-pyrrolyl, R<sub>7</sub> is hydrogen or halogen, and D is a group of formula IV wherein R<sub>8</sub> is hydrogen, (C<sub>1-4</sub>)alkyl or benzyl or a group of formula V wherein the free bond is attached to the 3 position and subject to the proviso to formula I in claim 2 as well as acid addition salt and quaternary ammonium salts thereof.
16. A compound of claim 6 which is N-(endo-9-methyl-aza-bicyclo[3.3.1]non-3-yl) indol-3-yl 10  
carboxylic acid amide as well as acid addition salts and quaternary ammonium salts thereof.
17. A compound of claim 6 which is indol-3-yl carboxylic acid endo-8-methyl-8-aza-  
bicyclo[3.2.1]oct-3-yl ester as well as acid addition salts and quaternary ammonium salts thereof.
18. A compound of claim 6 which is 1-methyl-N-(endo-9-methyl-aza-bicyclo[3.3.1]non-3-yl) 15  
indol-3-yl carboxylic acid amide as well as acid addition salts and quaternary ammonium salts thereof.
19. A compound of claim 6 which is 5-fluoro-1-methyl-indol-3-yl carboxylic acid endo-9-aza- 15  
bicyclo[3.3.1]non-3-yl ester as well as acid addition salts and quaternary ammonium salts thereof.
20. A compound of claim 6 which is 2-methoxy-indol-3-yl carboxylic acid endo-8-methyl-8-aza-  
bicyclo[3.2.1]oct-3-yl ester as well as acid addition salts and quaternary ammonium salts thereof.
21. A compound of claim 6 which is 2-chloro-indol-3-yl carboxylic acid endo-8-methyl-8-aza- 20  
bicyclo[3.2.1]oct-3-yl ester as well as acid addition salts and quaternary ammonium salts thereof.
22. A compound of claim 6 which is 3-iodo-indol-4-yl carboxylic acid endo-8-methyl-8-aza-  
bicyclo[3.2.1]oct-3-yl ester as well as acid addition salts and quaternary ammonium salts thereof.
23. A compound of claim 6 which is 5-chloro-2-methoxy-4-methylamino-benzoic acid 1-aza-  
bicyclo[2.2.2]oct-3-yl ester as well as acid addition salts and quaternary ammonium salts thereof.
24. A compound of claim 6 which is 4-amino-5-chloro-2-methoxy benzoic acid exo-8-benzyl-8- 25  
aza-bicyclo[3.2.1]oct-3-yl ester as well as acid addition salts and quaternary ammonium salts thereof.
25. A compound of claim 6 which is 4-amino-5-chloro-2-methoxy-benzoic acid exo-8-  
bicyclo[3.2.1]oct-3-yl ester as well as acid addition salts and quaternary ammonium salts thereof.
26. A compound of claim 6 which is indol-4-yl carboxylic acid endo-8-methyl-8-aza- 30  
bicyclo[3.2.1]oct-3-yl ester as well as acid addition salts and quaternary ammonium salts thereof.
27. A compound of claim 6 which is indol-4-yl carboxylic acid endo-9-methyl-9-aza-  
bicyclo[3.3.1]non-3-yl ester as well as acid addition salts and quaternary ammonium salts thereof.
28. A compound of claim 6 wherein D is a group of formula IV and A, B, n, R<sub>8</sub> and the 35  
configuration of the moiety B—D is 5-chloro-indolyl-3-yl, O, 2, CH<sub>3</sub> and endo, as well as acid addition salts and quaternary ammonium salts thereof.
29. A compound of claim 6 wherein D is a group of formula IV and A, B, n, R<sub>8</sub> and the 35  
configuration of the moiety B—D is 4-methoxy-indol-3-yl, O, 2, CH<sub>3</sub> and endo, as well as acid addition salts and quaternary ammonium salts thereof.
30. A compound of claim 6 wherein D is a group of formula IV and A, B, n, R<sub>8</sub> and the 40  
configuration of the moiety B—D is 5-methoxy-indol-3-yl, O, 2, CH<sub>3</sub> and endo, as well as acid addition salts and quaternary ammonium salts thereof.
31. A compound of claim 6 wherein D is a group of formula IV and A, B, n, R<sub>8</sub> and the 40  
configuration of the moiety B—D is 1-methyl-indol-3-yl, O, 2, CH<sub>3</sub> and endo, as well as acid addition salts and quaternary ammonium salts thereof.
32. A compound of claim 6 wherein D is a group of formula IV and A, B, n, R<sub>8</sub> and the 45  
configuration of the moiety B—D is indol-3-yl, O, 2, CH<sub>3</sub> and exo, as well as acid addition salts and quaternary ammonium salts thereof.
33. A compound of claim 6 wherein D is a group of formula IV and A, B, n, R<sub>8</sub> and the 45  
configuration of the moiety B—D is indol-3-yl, O, 3, CH<sub>3</sub> and endo, as well as acid addition salts and quaternary ammonium salts thereof.
34. A compound of claim 6 wherein D is a group of formula IV and A, B, n, R<sub>8</sub> and the 50  
configuration of the moiety B—D is indol-3-yl, O, 2, n-C<sub>3</sub>H<sub>7</sub> and endo, as well as acid addition salts and quaternary ammonium salts thereof.
35. A compound of claim 6 wherein D is a group of formula IV and A, B, n, R<sub>8</sub> and the 50  
configuration of the moiety B—D is indol-3-yl, O, 2, benzyl and exo, as well as acid addition salts and quaternary ammonium salts thereof.
36. A compound of claim 6 wherein D is a group of formula IV and A, B, n, R<sub>8</sub> and the 55  
configuration of the moiety B—D is indol-3-yl, O, 2, benzyl and endo, as well as acid addition salts and quaternary ammonium salts thereof.
37. A compound of claim 6 wherein D is a group of formula IV and A, B, n, R<sub>8</sub> and the 60  
configuration of the moiety B—D is indol-3-yl, O, 2, H and endo, as well as acid addition salts and quaternary ammonium salts thereof.
38. A compound of claim 6 wherein D is a group of formula IV and A, B, n, R<sub>8</sub> and the 60  
configuration of the moiety B—D is 5-fluoro-indol-3-yl, O, 3, H and endo, as well as acid addition salts and quaternary ammonium salts thereof.

- [illegible]

configuration of the moiety B—D is benzofuran-3-yl, O, 3, CH<sub>3</sub> and endo, as well as acid addition salts and quaternary ammonium salts thereof.

61. A compound of claim 6 wherein D is a group of formula IV and A, B, n, R<sub>8</sub> and the configuration of the moiety B—D is 1(H)-inden-3-yl, NH, 3, CH<sub>3</sub> and endo, as well as acid addition salts and quaternary ammonium salts thereof. 5
62. A compound of claim 6 wherein D is a group of formula IV and A, B, n, R<sub>8</sub> and the configuration of the moiety B—D is indol-3-yl, NH, 4, CH<sub>3</sub> and endo, as well as acid addition salts and quaternary ammonium salts thereof.
63. A compound of claim 6 wherein D is a group of formula IV and A, B, n, R<sub>8</sub> and the configuration of the moiety B—D is indol-5-yl, O, 2, CH<sub>3</sub> and endo, as well as acid addition salts and quaternary ammonium salts thereof. 10
64. A compound of claim 6 wherein D is a group of formula IV and A, B, n, R<sub>8</sub> and the configuration of the moiety B—D is indol-5-yl, O, 2, CH<sub>3</sub> and endo, as well as acid addition salts and quaternary ammonium salts thereof.
65. A compound of claim 6 wherein D is a group of formula IV and A, B, n, R<sub>8</sub> and the configuration of the moiety B—D is indol-5-yl, O, 3, CH<sub>3</sub> and endo, as well as acid addition salts and quaternary ammonium salts thereof. 15
66. A compound of claim 6 wherein D is a group of formula IV and A, B, n, R<sub>8</sub> and the configuration of the moiety B—D is 3-iodo-indol-5-yl, O, 3, CH<sub>3</sub> and endo, as well as acid addition salts and quaternary ammonium salts thereof. 20
67. A compound of claim 6 wherein D is a group of formula IV and A, B, n, R<sub>8</sub> and the configuration of the moiety B—D is indol-4-yl, NH, 2, CH<sub>3</sub> and exo, as well as acid addition salts and quaternary ammonium salts thereof.
68. A compound of claim 6 wherein D is a group of formula IV and A, B, n, R<sub>8</sub> and the configuration of the moiety B—D is indol-4-yl, NH, 2, CH<sub>3</sub> and endo, as well as acid addition salts and quaternary ammonium salts thereof. 25
69. A compound of claim 6 wherein D is a group of formula IV and A, B, n, R<sub>8</sub> and the configuration of the moiety B—D is indol-5-yl, NH, 2, CH<sub>3</sub> and endo, as well as acid addition salts and quaternary ammonium salts thereof.
70. A compound of claim 6 wherein D is a group of formula IV and A, B, n, R<sub>8</sub> and the configuration of the moiety B—D is 5-chloro-2-methoxy-4-methylaminophenyl, O, 2, CH<sub>3</sub>, Endo, as well as acid addition salts and quaternary ammonium salts thereof. 30
71. A compound of claim 6 wherein D is a group of formula IV and A, B, n, R<sub>8</sub> and the configuration of the moiety B—D is 2-methyl-4-dimethylaminophenyl, O, 2, benzyl, endo, as well as acid addition salts and quaternary ammonium salts thereof. 35
72. A compound of claim 6 wherein D is a group of formula IV and A, B, n, R<sub>8</sub> and the configuration of the moiety B—D is 4-amino-5-chloro-2-methoxyphenyl, O, 2, CH<sub>3</sub>, endo, as well as acid addition salts and quaternary ammonium salts thereof.
73. A compound of claim 6 wherein D is a group of formula IV and A, B, n, R<sub>8</sub> and the configuration of the moiety B—D is 4-amino-5-chloro-2-methoxyphenyl, O, 2, H, endo, as well as acid addition salts and quaternary ammonium salts thereof. 40
74. A compound of claim 6 wherein D is a group of formula IV and A, B, n, R<sub>8</sub> and the configuration of the moiety B—D is 4-amino-2-methoxyphenyl, O, 2, H, endo, as well as acid addition salts and quaternary ammonium salts thereof.
75. A compound of claim 6 wherein D is a group of formula IV and A, B, n, R<sub>8</sub> and the configuration of the moiety B—D is 4-amino-2-methoxyphenyl, O, 2, H, exo, as well as acid addition salts and quaternary ammonium salts thereof. 45
76. A compound of claim 6 wherein D is a group of formula IV and A, B, n, R<sub>8</sub> and the configuration of the moiety B—D is 4-amino-2-methoxyphenyl, O, 2, CH<sub>3</sub>, endo, as well as acid addition salts and quaternary ammonium salts thereof. 50
77. A compound of claim 6 wherein D is a group of formula IV and A, B, n, R<sub>8</sub> and the configuration of the moiety B—D is 5-chloro-2-methoxy-4-dimethylaminophenyl, O, 2, CH<sub>3</sub>, endo, as well as acid addition salts and quaternary ammonium salts thereof.
78. A compound of claim 6 wherein D is a group of formula IV and A, B, n, R<sub>8</sub> and the configuration of the moiety B—D is 2-chloro-4-aminophenyl, O, 2, CH<sub>3</sub>, endo, as well as acid addition salts and quaternary ammonium salts thereof. 55
79. A compound of claim 6 wherein D is a group of formula IV and A, B, n, R<sub>8</sub> and the configuration of the moiety B—D is 3-iodo-4-amino-2-methoxyphenyl, O, 2, CH<sub>3</sub>, endo, as well as acid addition salts and quaternary ammonium salts thereof.
80. A compound of claim 6 wherein D is a group of formula IV and A, B, n, R<sub>8</sub> and the configuration of the moiety B—D is 3-iodo-4-methylamino-2-methoxyphenyl, O, 2, CH<sub>3</sub>, endo, as well as acid addition salts and quaternary ammonium salts thereof. 60
81. A compound of claim 6 wherein D is a group of formula IV and A, B, n, R<sub>8</sub> and the configuration of the moiety B—D is 2-methoxy-4-methylamino-phenyl, O, 3, CH<sub>3</sub>, endo, as well as acid addition salts and quaternary ammonium salts thereof. 65

82. A compound of claim 6 wherein D is a group of formula IV and A, B, n, R<sub>8</sub> and the configuration of the moiety B—D is 2-chloro-4-nitrophenyl, O, 2, CH<sub>3</sub>, endo, as well as acid addition salts and quaternary ammonium salts thereof.
83. A compound of claim 6 wherein A is indolyl-3-yl B is —O—, and D is 3-quinuclidinyl as well  
5 as acid addition salts and quaternary ammonium salts thereof. 5
84. A compound of claim 6 wherein A is 5-chloro-2-methoxy-4-methylaminophenyl, B is —NH— and D is 3-quinuclidinyl as well as acid addition salts and quaternary ammonium salts thereof.
85. A compound of claim 6 wherein A is 4-bromo-2-methoxyphenyl, B is O, D is a formula IV, with the endo configuration, n is 2, and R<sub>8</sub> is methyl, and acid addition salts and quaternary ammonium  
10 salts thereof. 10
86. A compound of claim 6 wherein A is 3,5-dichlorophenyl, B is O, D is a formula IV, with the endo configuration, n is 3, and R<sub>8</sub> is methyl, and acid addition salts and quaternary ammonium salts thereof.
87. A compound of claim 6 wherein A is 5-chloro-2-methoxy-4-(1-pyrrolyl)phenyl, B is O, D is a  
15 formula IV, with the endo configuration, n is 2, and R<sub>8</sub> is methyl, and acid addition salts and quaternary ammonium salts thereof. 15
88. A compound of claim 6 wherein A is 2-methoxy-4-(1-pyrrolyl)phenyl, B is O, D is a formula IV, with the endo configuration, n is 2, and R<sub>8</sub> is methyl, and acid addition salts and quaternary ammonium salts thereof.
89. A compound of claim 6 wherein A is 3,5-dichlorophenyl, B is O, and D is 3-quinuclidinyl, and  
20 acid addition salts and quaternary ammonium salts thereof. 20
90. A compound of claim 6 wherein D is a compound of formula IV, and acid addition salts and quaternary ammonium salts thereof.
91. A compound of claim 90 wherein n is 3, and acid addition salts and quaternary ammonium  
25 salts thereof. 25
92. A compound of claim 6 wherein D is a compound of formula V, and acid addition salts and quaternary ammonium salts thereof.
93. A compound of claim 6 wherein A is indolyl and acid addition salts and quaternary ammonium salts thereof.
94. A compound of any one of claims 4 to 93 or a pharmaceutically acceptable acid addition salt  
30 or quaternary ammonium salt for use as a pharmaceutical. 30
95. A compound of any one of claims 4 to 93 or a pharmaceutically acceptable acid addition salt or quaternary ammonium salt thereof for use as a serotonin M antagonist, an analgesic agent, an anti-migraine agent or an anti-arrhythmic agent.
96. A pharmaceutical composition comprising a compound of any one of claims 4 to 93 or  
35 pharmaceutically acceptable acid addition salt or quaternary ammonium salt thereof in association with a pharmaceutical carrier or diluent. 35
97. A compound of formula VII as defined in claim 2 wherein B is NH and D is a group of formula IV wherein n is 4.